



FORM PTO - 1449

SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME                   | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|------------------------|-------|--------------|-------------------------------|
| RD             | A67 | 6,617,135          | 9/9/03   | Gillies <i>et al.</i>  |       |              |                               |
|                | A68 | 6,485,726 B1       | 11/26/02 | Blumberg <i>et al.</i> |       |              |                               |
|                | A69 | 6,475,717 B1       | 11/5/02  | Enssle <i>et al.</i>   |       |              |                               |
|                | A70 | 6,335,176 B1       | 1/1/02   | Inglese <i>et al.</i>  |       |              |                               |
|                | A71 | 2003/0166877 A1    | 9/4/03   | Gillies <i>et al.</i>  |       |              |                               |
|                | A72 | 2003/0166163 A1    | 9/4/03   | Gillies                |       |              |                               |
|                | A73 | 2003/0157054 A1    | 8/21/03  | Gillies <i>et al.</i>  |       |              |                               |
|                | A74 | 2003/0105294 A1    | 6/5/03   | Gillies <i>et al.</i>  |       |              |                               |
|                | A75 | 2003/0049227 A1    | 3/13/03  | Gillies <i>et al.</i>  |       |              |                               |
|                | A76 | 2003/0044423 A1    | 3/6/03   | Gillies <i>et al.</i>  |       |              |                               |
|                | A77 | 2002/0193570 A1    | 12/19/02 | Gillies <i>et al.</i>  |       |              |                               |
|                | A78 | 2002/0192222 A1    | 12/19/02 | Blumberg <i>et al.</i> |       |              |                               |
|                | A79 | 2002/0147311 A1    | 10/10/02 | Gillies <i>et al.</i>  |       |              |                               |
| RD             | A80 | 2002/0081664 A1    | 6/27/02  | Lo <i>et al.</i>       |       |              |                               |
|                | A81 | 2001/0053539 A1    | 12/20/01 | Lauffer <i>et al.</i>  |       |              |                               |

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |      | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|----------------|------|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| RD             | B96  | 1 088 888 A1       | 4/4/01   | EP              |       |              |                |                  | Y                        |
|                | B97  | WO 03/077834 A2    | 9/2/03   | PCT             |       |              |                |                  | Y                        |
|                | B98  | WO 03/048334 A2    | 6/12/03  | PCT             |       |              |                |                  | Y                        |
|                | B99  | WO 02/090566 A2    | 11/14/02 | PCT             |       |              |                |                  | Y                        |
|                | B100 | WO 02/079415 A2    | 10/10/02 | PCT             |       |              |                |                  | Y                        |
|                | B101 | WO 02/079232 A2    | 10/10/02 | PCT             |       |              |                |                  | Y                        |
|                | B102 | WO 02/072605 A2    | 9/19/02  | PCT             |       |              |                |                  | Y                        |
| RD             | B103 | WO 02/066514 A2    | 8/29/02  | PCT             |       |              |                |                  | Y                        |

EXAMINER

DATE CONSIDERED

12/19/03

| FORM PTO - 1449                                  |  |   |         | ATTORNEY DOCKET NO.: MERCK-2056           |       |                 |                |                  |                          |
|--|--|---|---------|---|-------|-----------------|----------------|------------------|--------------------------|
| SUPPLEMENTAL<br>INFORMATION DISCLOSURE STATEMENT |  |   |         | APPLICANTS: Hartmann <i>et al.</i>        |       |                 |                |                  |                          |
|  |  |   |         | SERIAL NO.: 09/708,506                    |       | CONF. NO.: 2626 |                |                  |                          |
|  |  |   |         | FILING DATE: November 9, 2000 GROUP: 1647 |       |                 |                |                  |                          |
| FOREIGN PATENT DOCUMENTS                         |  |   |         |   |       |                 |                |                  |                          |
| EXAM.<br>INIT.                                   |  | DOCUMENT<br>NUMBER  | DATE    | COUNTRY<br>CODE                           | CLASS | SUB<br>CLASS    | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
| <i>RM</i>  | B104   | WO 02/02143 A2  | 1/10/02 | PCT                                       |       |                 |                |                  | Y                        |
|  | B105   | WO 01/58957 A2  | 8/16/01 | PCT                                       |       |                 |                |                  | Y                        |
| <i>RM</i>  | B106   | WO 01/36489 A2  | 5/25/01 | PCT                                       |       |                 |                |                  | Y                        |
| EXAM.<br>INIT.                                   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |         |   |       |                 |                |                  |                          |
| <i>RM</i>  | C182   | Angal et al. (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30:105-108.  |         |   |       |                 |                |                  |                          |
|  | C183   | Bitoni et al. (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.  |         |   |       |                 |                |                  |                          |
|  | C184   | Darling et al. (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.   |         |   |       |                 |                |                  |                          |
|  | C185   | Fibi et al. (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85:1229-1236.   |         |   |       |                 |                |                  |                          |
|  | C186   | Hammerling et al. (1996), "In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469. |         |   |       |                 |                |                  |                          |
|  | C187   | Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.   |         |   |       |                 |                |                  |                          |
|  | C188   | Locatelli et al. (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.   |         |   |       |                 |                |                  |                          |
|  | C189   | Spiekermann et al. (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.  |         |   |       |                 |                |                  |                          |
| <i>RM</i>  | C190   | Syed et al. (1998), "Efficiency of signalling through cytokine receptors depends critically on receptor orientation," <u>Nature</u> , 395:511-516.  |         |   |       |                 |                |                  |                          |
| EXAMINER <i>R M Keefy</i>                        |  |   |         | DATE CONSIDERED <i>12/19/03</i>           |       |                 |                |                  |                          |

FORM PTO - 1449  
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT.               |     | DOCUMENT<br>NUMBER | DATE     | NAME                            | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|------------------------------|-----|--------------------|----------|---------------------------------|-------|--------------|-------------------------------|
| <i>RA</i>                    | A1  | 07/348,237         | 5/5/89   | Rosenblum <i>et al.</i>         |       |              |                               |
|                              | A2  | 4,196,265          | 4/1/80   | Koprowski <i>et al.</i>         |       |              |                               |
|                              | A3  | 4,469,797          | 9/4/84   | Albarella                       |       |              |                               |
|                              | A4  | 4,676,980          | 6/30/87  | Segal <i>et al.</i>             |       |              |                               |
|                              | A5  | 4,816,567          | 3/28/89  | Cabilly <i>et al.</i>           |       |              |                               |
|                              | A6  | 4,946,778          | 8/7/90   | Ladner <i>et al.</i>            |       |              |                               |
|                              | A7  | 5,019,368          | 5/28/91  | Epstein <i>et al.</i>           |       |              |                               |
|                              | A8  | 5,073,627          | 12/17/91 | Curtis <i>et al.</i>            |       |              |                               |
|                              | A9  | 5,114,711          | 5/19/92  | Bell <i>et al.</i>              |       |              |                               |
|                              | A10 | 5,116,964          | 5/26/92  | Capon <i>et al.</i>             |       |              |                               |
|                              | A11 | 5,199,942          | 4/6/93   | Gillis                          |       |              |                               |
|                              | A12 | 5,225,538          | 7/6/93   | Capon <i>et al.</i>             |       |              |                               |
|                              | A13 | 5,225,539          | 7/6/93   | Winter                          |       |              |                               |
|                              | A14 | 5,258,498          | 11/2/93  | Huston <i>et al.</i>            |       |              |                               |
|                              | A15 | 5,314,995          | 5/24/94  | Fell, Jr. <i>et al.</i>         |       |              |                               |
|                              | A16 | 5,349,053          | 9/20/94  | Landolfi                        |       |              |                               |
|                              | A17 | 5,359,035          | 10/25/94 | Habermann                       |       |              |                               |
|                              | A18 | 5,514,582          | 5/7/96   | Capon <i>et al.</i>             |       |              |                               |
|                              | A19 | 5,538,866          | 7/23/96  | Israeli <i>et al.</i>           |       |              |                               |
|                              | A20 | 5,541,087          | 7/30/96  | Lo <i>et al.</i>                |       |              |                               |
|                              | A21 | 5,543,297          | 8/6/96   | Cromlish, <i>et al.</i>         |       |              |                               |
|                              | A22 | 5,552,524          | 09/03/96 | Basinski <i>et al.</i>          |       |              |                               |
| <i>RA</i>                    | A23 | 5,585,089          | 12/17/96 | Queen <i>et al.</i>             |       |              |                               |
| EXAMINER <i>R M 10/19/03</i> |     |                    |          | DATE CONSIDERED <i>12/19/03</i> |       |              |                               |



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT.             |     | DOCUMENT<br>NUMBER | DATE     | NAME                            | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------------------|-----|--------------------|----------|---------------------------------|-------|--------------|-------------------------------|
| RD                         | A24 | 5,609,846          | 3/11/97  | Goldenberg                      |       |              |                               |
|                            | A25 | 5,624,821          | 4/29/97  | Winter <i>et al.</i>            |       |              |                               |
|                            | A26 | 5,639,725          | 6/17/97  | O'Reilly <i>et al.</i>          |       |              |                               |
|                            | A27 | 5,645,835          | 7/8/97   | Fell, Jr. <i>et al.</i>         |       |              |                               |
|                            | A28 | 5,650,150          | 7/22/97  | Gillies                         |       |              |                               |
|                            | A29 | 5,650,492          | 7/22/97  | Gately <i>et al.</i>            |       |              |                               |
|                            | A30 | 5,667,776          | 9/16/97  | Zimmerman <i>et al.</i>         |       |              |                               |
|                            | A31 | 5,679,543          | 10/21/97 | Lawlis                          |       |              |                               |
|                            | A32 | 5,691,309          | 11/25/97 | Basinski <i>et al.</i>          |       |              |                               |
|                            | A33 | 5,709,859          | 1/20/98  | Aruffo <i>et al.</i>            |       |              |                               |
|                            | A34 | 5,719,266          | 02/17/98 | DiMarchi <i>et al.</i>          |       |              |                               |
|                            | A35 | 5,723,125          | 3/3/98   | Chang <i>et al.</i>             |       |              |                               |
|                            | A36 | 5,726,044          | 3/10/98  | Lo <i>et al.</i>                |       |              |                               |
|                            | A37 | 5,728,552          | 3/17/98  | Fujisawa <i>et al.</i>          |       |              |                               |
|                            | A38 | 5,733,876          | 3/31/98  | O'Reilly <i>et al.</i>          |       |              |                               |
|                            | A39 | 5,756,461          | 05/26/98 | Stephens                        |       |              |                               |
|                            | A40 | 5,759,551          | 6/2/98   | Ladd <i>et al.</i>              |       |              |                               |
|                            | A41 | 5,770,195          | 6/23/98  | Hudziak <i>et al.</i>           |       |              |                               |
|                            | A42 | 5,800,810          | 9/1/98   | Doyle <i>et al.</i>             |       |              |                               |
|                            | A43 | 5,807,715          | 9/15/98  | Morrison <i>et al.</i>          |       |              |                               |
|                            | A44 | 5,827,516          | 10/27/98 | Urban <i>et al.</i>             |       |              |                               |
|                            | A45 | 5,837,682          | 11/17/98 | Folkman <i>et al.</i>           |       |              |                               |
|                            | A46 | 5,843,423          | 12/1/98  | Lyman <i>et al.</i>             |       |              |                               |
|                            | A47 | 5,854,205          | 12/29/98 | O'Reilly <i>et al.</i>          |       |              |                               |
|                            | A48 | 5,858,347          | 1/12/99  | Baur <i>et al.</i>              |       |              |                               |
| RB                         | A49 | 5,885,795          | 3/23/99  | O'Reilly <i>et al.</i>          |       |              |                               |
| EXAMINER <i>R.M. 10039</i> |     |                    |          | DATE CONSIDERED <i>12/19/03</i> |       |              |                               |



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME                      | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|---------------------------|-------|--------------|-------------------------------|
| RP             | A50 | 5,886,178          | 3/23/99  | Allen <i>et al.</i>       |       |              |                               |
|                | A51 | 5,888,772          | 3/30/99  | Okasinski <i>et al.</i>   |       |              |                               |
|                | A52 | 5,908,626          | 6/1/99   | Chang <i>et al.</i>       |       |              |                               |
|                | A53 | 5,922,685          | 7/13/99  | Rakhmievich <i>et al.</i> |       |              |                               |
|                | A54 | 5,994,126          | 11/30/99 | Steinman <i>et al.</i>    |       |              |                               |
|                | A55 | 6,080,409          | 6/27/00  | Laus <i>et al.</i>        |       |              |                               |
|                | A56 | 6,086,875          | 7/11/00  | Blumberg <i>et al.</i>    |       |              |                               |
|                | A57 | 6,100,387          | 8/8/00   | Herrmann <i>et al.</i>    |       |              |                               |
|                | A58 | 6,169,070 B1       | 1/2/01   | Chen <i>et al.</i>        |       |              |                               |
|                | A59 | 6,171,588 B1       | 1/9/01   | Carron <i>et al.</i>      |       |              |                               |
|                | A60 | 6,277,375 B1       | 8/21/01  | Ward                      |       |              |                               |
|                | A61 | 6,348,192 B1       | 2/19/02  | Chan <i>et al.</i>        |       |              |                               |
|                | A62 | 6,406,689 B1       | 6/18/02  | Falkenberg <i>et al.</i>  |       |              |                               |
|                | A63 | 6,444,792 B1       | 9/3/02   | Gray <i>et al.</i>        |       |              |                               |
|                | A64 | 5,856,298          | 1/5/99   | Strickland                |       |              |                               |
|                | A65 | 5,688,679          | 11/18/97 | Powell                    |       |              |                               |
| RP             | A66 | 5,441,868          | 8/15/95  | Lin                       |       |              |                               |


## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |    | DOCUMENT<br>NUMBER | DATE     | COUNT<br>RY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|----------------|----|--------------------|----------|---------------------|-------|--------------|----------------|------------------|--------------------------|
| RP             | B1 | 0 158 198 A1       | 10/16/85 | EP                  |       |              |                |                  | Y                        |
|                | B2 | 0 211 769 A2       | 2/25/87  | EP                  |       |              |                |                  | Y                        |
|                | B3 | 0 256 714 A2       | 2/24/88  | EP                  |       |              |                |                  | Y                        |
|                | B4 | 0 294 703 A2       | 12/14/88 | EP                  |       |              |                |                  | Y                        |
|                | B5 | 0 308 936 B1       | 3/29/89  | EP                  |       |              |                |                  | Y                        |
| RP             | B6 | 0 314 317 B1       | 5/3/89   | EP                  |       |              |                |                  | Y                        |

EXAMINER

DATE CONSIDERED

12/19/03



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT.            |     | DOCUMENT<br>NUMBER | DATE    | COUNT<br>RY<br>CODE | CLASS                           | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY                                | ENGLISH<br>LANG<br>(Y/N) |
|---------------------------|-----|--------------------|---------|---------------------|---------------------------------|--------------|----------------|---|--------------------------|
| ms                        | B7  | 0 318 554 B1       | 6/7/89  | EP                  |                                 |              |                |   | Y                        |
|                           | B8  | 0 319 012 A2       | 6/7/89  | EP                  |                                 |              |                |   | Y                        |
|                           | B9  | 0 326 120 B1       | 8/2/89  | EP                  |                                 |              |                |   | Y                        |
|                           | B10 | 0 350 230 A2       | 1/10/90 | EP                  |                                 |              |                |   | Y                        |
|                           | B11 | 0 375 562 B1       | 6/27/90 | EP                  |                                 |              |                |   | Y                        |
|                           | B12 | 0 396 387 A2       | 11/7/90 | EP                  |                                 |              |                |   | Y                        |
|                           | B13 | 0 439 095 A2       | 7/31/91 | EP                  |                                 |              |                |   | Y                        |
|                           | B14 | 0 511 747 A1       | 11/4/92 | EP                  |                                 |              |                |   | Y                        |
|                           | B15 | 0 601 043 B1       | 6/15/94 | EP                  |                                 |              |                |   | Y                        |
|                           | B16 | 0 706 799 A2       | 4/17/96 | EP                  |                                 |              |                |   | Y                        |
|                           | B17 | 0 790 309 A1       | 8/20/97 | EP                  |                                 |              |                |   | Y                        |
|                           | B18 | 21725/88           | 3/23/89 | AU                  |                                 |              |                |   | Y                        |
|                           | B19 | 93100115.3         | 7/14/93 | CN                  |                                 |              |                |   | N                        |
|                           | B20 | 93100115.3         | 7/14/93 | CN                  |                                 |              |                | Y   | Y                        |
|                           | B21 | 37 12985 A1        | 11/3/88 | DE                  |                                 |              |                |   | N                        |
|                           | B22 | 37 12985           | 11/2/88 | DE                  |                                 |              |                | Y   | Y                        |
|                           | B23 | 2 292 382 A        | 2/21/96 | GB                  |                                 |              |                |   | Y                        |
|                           | B24 | 63-267278          | 11/4/88 | JP                  |                                 |              |                |   | N                        |
|                           | B25 | 63-267278          | 11/4/88 | JP                  |                                 |              |                | Y   | Y                        |
|                           | B26 | 63-267296          | 11/4/88 | JP                  |                                 |              |                |   | N                        |
|                           | B27 | 63-267296          | 11/4/88 | JP                  |                                 |              |                | Y   | Y                        |
|                           | B28 | 0 237 019 A2       | 9/16/87 | EP                  |                                 |              |                | English<br>counterpart of<br>63-267296<br>(B26) | Y                        |
|                           | B29 | WO 86/01533        | 3/13/86 | PCT                 |                                 |              |                |   | Y                        |
| ms                        | B30 | WO 88/00052        | 1/14/88 | PCT                 |                                 |              |                |   | Y                        |
| EXAMINER <i>Km Koerby</i> |     |                    |         |                     | DATE CONSIDERED <i>12/19/02</i> |              |                |   |                          |

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY       | ENGLISH<br>LANG<br>(Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|------------------------|--------------------------|
| <i>RM</i>      | B31 | WO 88/09344        | 12/1/88  | PCT             |       |              |                |                        | Y                        |
|                | B32 | WO 89/02922        | 4/6/89   | PCT             |       |              |                |                        | Y                        |
|                | B33 | WO 89/09620        | 10/19/89 | PCT             |       |              |                | Abstract in<br>English | N                        |
|                | B34 | WO 90/03801        | 4/19/90  | PCT             |       |              |                |                        | Y                        |
|                | B35 | WO 91/00360        | 1/10/91  | PCT             |       |              |                |                        | Y                        |
|                | B36 | WO 91/04329        | 04/04/91 | PCT             |       |              |                |                        | Y                        |
|                | B37 | WO 91/08298        | 6/13/91  | PCT             |       |              |                |                        | Y                        |
|                | B38 | WO 91/13166        | 9/5/91   | PCT             |       |              |                |                        | Y                        |
|                | B39 | WO 91/14438        | 10/3/91  | PCT             |       |              |                |                        | Y                        |
|                | B40 | WO 92/02240        | 2/20/92  | PCT             |       |              |                |                        | Y                        |
|                | B41 | WO 92/08495        | 5/29/92  | PCT             |       |              |                |                        | Y                        |
|                | B42 | WO 92/08801        | 5/29/92  | PCT             |       |              |                |                        | Y                        |
|                | B43 | WO 92/16562        | 10/1/92  | PCT             |       |              |                |                        | Y                        |
|                | B44 | WO 93/03157        | 2/18/93  | PCT             |       |              |                |                        | Y                        |
|                | B45 | WO 93/10229        | 5/27/93  | PCT             |       |              |                |                        | Y                        |
|                | B46 | WO 95/05468        | 2/23/95  | PCT             |       |              |                |                        | Y                        |
|                | B47 | WO 95/21258        | 8/10/95  | PCT             |       |              |                |                        | Y                        |
|                | B48 | WO 95/28427        | 10/26/95 | PCT             |       |              |                |                        | Y                        |
|                | B49 | WO 95/31483        | 11/23/95 | PCT             |       |              |                |                        | Y                        |
|                | B50 | WO 96/04388        | 02/15/96 | PCT             |       |              |                |                        | Y                        |
|                | B51 | WO 96/05309        | 2/22/96  | PCT             |       |              |                |                        | Y                        |
|                | B52 | WO 96/08570        | 3/21/96  | PCT             |       |              |                |                        | Y                        |
|                | B53 | WO 96/18412        | 6/20/96  | PCT             |       |              |                |                        | Y                        |
| <i>RM</i>      | B54 | WO 96/31526        | 10/10/96 | PCT             |       |              |                |                        | Y                        |

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT.            |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS                           | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|---------------------------|-----|--------------------|----------|-----------------|---------------------------------|--------------|----------------|------------------|--------------------------|
| hs                        | B55 | WO 97/00317        | 1/3/97   | PCT             |                                 |              |                |                  | Y                        |
|                           | B56 | WO 97/00319        | 1/3/97   | PCT             |                                 |              |                |                  | Y                        |
|                           | B57 | WO 97/15666        | 5/1/97   | PCT             |                                 |              |                |                  | Y                        |
|                           | B58 | WO 97/20062        | 6/5/97   | PCT             |                                 |              |                |                  | Y                        |
|                           | B59 | WO 97/24137        | 7/10/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B60 | WO 97/24440        | 7/10/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B61 | WO 97/26335        | 7/24/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B62 | WO 97/30089        | 8/21/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B63 | WO 97/33617        | 9/18/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B64 | WO 97/33619        | 9/18/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B65 | WO 97/34631        | 9/25/97  | PCT             |                                 |              |                |                  | Y                        |
|                           | B66 | WO 97/43316        | 11/20/97 | PCT             |                                 |              |                |                  | Y                        |
|                           | B67 | WO 98/00127        | 1/8/98   | PCT             |                                 |              |                |                  | Y                        |
|                           | B68 | WO 98/06752        | 2/19/98  | PCT             |                                 |              |                |                  | Y                        |
|                           | B69 | WO 98/28427        | 7/2/98   | PCT             |                                 |              |                |                  | Y                        |
|                           | B70 | WO 98/30706        | 7/16/98  | PCT             |                                 |              |                |                  | Y                        |
|                           | B71 | WO 98/46257        | 10/22/98 | PCT             |                                 |              |                |                  | Y                        |
|                           | B72 | WO 98/59244        | 12/30/98 | PCT             |                                 |              |                |                  | Y                        |
|                           | B73 | WO 99/02709        | 01/21/99 | PCT             |                                 |              |                |                  | Y                        |
|                           | B74 | WO 99/03887        | 01/28/99 | PCT             |                                 |              |                |                  | Y                        |
|                           | B75 | WO 99/29732        | 6/17/99  | PCT             |                                 |              |                |                  | Y                        |
|                           | B76 | WO 99/43713        | 9/2/99   | PCT             |                                 |              |                |                  | Y                        |
|                           | B77 | WO 99/52562        | 10/21/99 | PCT             |                                 |              |                |                  | Y                        |
| hs                        | B78 | WO 99/53958        | 10/28/99 | PCT             |                                 |              |                |                  | Y                        |
| EXAMINER <i>R M Kelly</i> |     |                    |          |                 | DATE CONSIDERED <i>12/19/03</i> |              |                |                  |                          |





FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| AK             | B79 | WO 99/60128        | 11/25/99 | PCT             |       |              |                |                  | Y                        |
|                | B80 | WO 99/62944        | 12/09/99 | PCT             |       |              |                |                  | Y                        |
|                | B81 | WO 00/11033        | 3/2/00   | PCT             |       |              |                |                  | Y                        |
|                | B82 | WO 00/34317        | 06/15/00 | PCT             |       |              |                |                  | Y                        |
|                | B83 | WO 00/40615        | 7/13/00  | PCT             |       |              |                |                  | Y                        |
|                | B84 | WO 00/69913        | 11/23/00 | PCT             |       |              |                |                  | Y                        |
|                | B85 | WO 00/78334 A1     | 12/28/00 | PCT             |       |              |                |                  | Y                        |
|                | B86 | WO 01/07081 A1     | 2/1/01   | PCT             |       |              |                |                  | Y                        |
|                | B87 | WO 01/10912 A1     | 2/15/01  | PCT             |       |              |                |                  | Y                        |
|                | B88 | WO 03/015697 A2    | 2/27/03  | PCT             |       |              |                |                  | Y                        |
|                | B89 | 0 640 619 A1       | 3/1/95   | EP              |       |              |                |                  | Y                        |
|                | B90 | 0 668 353 A1       | 8/23/95  | EP              |       |              |                |                  | Y                        |
|                | B91 | WO 94/24160        | 10/27/94 | PCT             |       |              |                |                  | Y                        |
|                | B92 | WO 94/25055        | 11/10/94 | PCT             |       |              |                |                  | Y                        |
|                | B93 | WO 99/66054        | 12/23/99 | PCT             |       |              |                |                  | Y                        |
|                | B94 | WO 00/68376        | 11/16/00 | PCT             |       |              |                |                  | Y                        |
| AK             | B95 | WO 00/24893        | 5/4/00   | PCT             |       |              |                |                  | Y                        |

EXAM.  
INIT.




OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)


|    |    |  |
|----|----|--|
| AK | C1 | Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," <u>Journal of Protein Chemistry</u> , 11:5:433-444. |
|    | C2 | Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54:2:83-94.  |
| AK | C3 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.  |

EXAMINER

DATE CONSIDERED


12/19/03

|   |  |  |                          |
|---|--|--|--------------------------|
| FORM PTO - 1449<br>INFORMATION DISCLOSURE STATEMENT                                 |  | ATTORNEY DOCKET NO.: MERCK-2056<br>APPLICANTS: Hartmann <i>et al.</i><br>SERIAL NO.: 09/708,506      CONF. NO.: 2626<br>FILING DATE: November 9, 2000      GROUP: 1647   |                          |
| EXAM.<br>INIT.  | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |                          |
|    | C4   | Arenberg et al. (1996), "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.                                      |                          |
|   | C5   | Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Experimental Medicine</u> , 167:612-622  |                          |
|   | C6   | Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856. |                          |
|   | C7   | Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.  |                          |
|   | C8   | Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin <sup>TM</sup> ) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.    |                          |
|   | C9   | Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263.  |                          |
|   | C10  | Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Mol. Immunol.</u> , 30:379-386.  |                          |
|   | C11  | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.  |                          |
|   | C12  | Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.  |                          |
|   | C13  | Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.  |                          |
|   | C14  | Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193.  |                          |
|   | C15  | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.  |                          |
|   | C16  | Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Nature</u> , 390:404-407.   |                          |
|  | C17  | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.   |                          |
| EXAMINER  |     |  | DATE CONSIDERED 12/17/03 |


|   |  |  |                          |
|---|--|--|--------------------------|
| FORM PTO - 1449<br>INFORMATION DISCLOSURE STATEMENT |  | ATTORNEY DOCKET NO.: MERCK-2056<br>APPLICANTS: Hartmann <i>et al.</i><br>SERIAL NO.: 09/708,506      CONF. NO.: 2626<br>FILING DATE: November 9, 2000      GROUP: 1647   |                          |
| EXAM.<br>INIT.                                      | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |                          |
|   | C18  | Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.  |                          |
|   | C19  | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.   |                          |
|   | C20  | Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138. |                          |
|   | C21  | Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , 173:6:1483-1491.  |                          |
|   | C22  | Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , 271:46:29461-29467.   |                          |
|   | C23  | Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272:36:22924-22928.   |                          |
|   | C24  | Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , 337:525-531.  |                          |
|   | C25  | Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.  |                          |
|   | C26  | Chan et al., (1991), "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.  |                          |
|   | C27  | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.   |                          |
|   | C28  | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.   |                          |
|   | C29  | Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , 335:370-372.   |                          |
|   | C30  | Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <u>Nature</u> , 339:394-397.  |                          |
|   | C31  | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159:1:351-358.                              |                          |
|   | C32  | Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.  |                          |
| EXAMINER  |     |  | DATE CONSIDERED 12/19/00 |


|   |  |   |  |
|---|--|---|--|
| FORM PTO - 1449<br>INFORMATION DISCLOSURE STATEMENT |  | ATTORNEY DOCKET NO.: MERCK-2056<br>APPLICANTS: Hartmann <i>et al.</i><br>SERIAL NO.: 09/708,506      CONF. NO.: 2626<br>FILING DATE: November 9, 2000      GROUP: 1647  |  |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |  |
| <i>PO</i>   | C33  | Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.  |  |
|   | C34  | Cohen, S. L. et al., (1996), "Human leptin characterization," <u>Nature</u> , 382:589.  |  |
|   | C35  | Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.  |  |
|   | C36  | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.                   |  |
|   | C37  | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.   |  |
|   | C38  | D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.  |  |
|   | C39  | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.  |  |
|   | C40  | Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , 95:10443-10448.  |  |
|   | C41  | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166.  |  |
|   | C42  | Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> 31:342-348. |  |
|   | C43  | Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:7:2446-2452.                   |  |
|   | C44  | Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:15552-15558.  |  |
|   | C45  | Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," <u>Nature</u> , 395:763-770.   |  |
|   | C46  | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.   |  |
|   | C47  | Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.  |  |
| <i>PO</i>   | C48  | Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.   |  |
| EXAMINER <i>RM Korb</i>                             |  | DATE CONSIDERED <i>12/19/07</i>   |  |

|   |   |  |  |
|---|---|--|--|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.:</b> MERCK-2056<br><b>APPLICANTS:</b> Hartmann <i>et al.</i><br><b>SERIAL NO.:</b> 09/708,506 <b>CONF. NO.:</b> 2626<br><b>FILING DATE:</b> November 9, 2000 <b>GROUP:</b> 1647       |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |  |  |
|   | C49   | Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.   |  |
|   | C50   | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.   |  |
|   | C51   | Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> , 1:1:47-54.                    |  |
|   | C52   | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , 89:1428-1432.  |  |
|   | C53   | Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235.   |  |
|   | C54   | Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>J. Immunology</u> , 160:2:6195-6203.                              |  |
|   | C55   | Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.                           |  |
|   | C56   | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , 120:6:2027-2032.  |  |
|   | C57   | Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.  |  |
|   | C58   | Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , 269:91-95.   |  |
|   | C59   | Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.  |  |
|   | C60   | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:8:2081-2805. |  |
|   | C61   | Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148.   |  |
|   | C62   | Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Tibtech</u> , 11:42-44.  |  |
|   | C63   | Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotech.</u> , 1:95-105.         |  |
|   | C64   | Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," <u>Journal of Immunology</u> , 157:7:3165-3170.                                     |  |
| <b>EXAMINER</b>   |   | <b>DATE CONSIDERED</b> 12/19/03  |  |



|   |   |  |  |
|---|---|--|--|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.: MERCK-2056</b><br><b>APPLICANTS: Hartmann et al.</b><br><b>SERIAL NO.: 09/708,506</b> <b>CONF. NO.: 2626</b><br><b>FILING DATE: November 9, 2000</b> <b>GROUP: 1647</b>  |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |  |  |
|   | C65   | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11:6:629-636.                                   |  |
|   | C66   | He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> , 1029-1035.   |  |
|   | C67   | Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338.  |  |
|   | C68   | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunol.</u> , 158:4:381-4388.  |  |
|   | C69   | Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:18: 7059-7063.   |  |
|   | C70   | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.   |  |
|   | C71   | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7:2:159-167.                                      |  |
|   | C72   | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17:6:1656-1664.   |  |
|   | C73   | Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675.                                  |  |
|   | C74   | Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.   |  |
|   | C75   | Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , 28:9:1027-1037.  |  |
|   | C76   | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096:4:345-354 (Abstract). |  |
|   | C77   | Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.                               |  |
|   | C78   | Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.  |  |
|   | C79   | Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14:4:1779-1789.   |  |
| <b>EXAMINER</b>   |   | <b>DATE CONSIDERED</b> 12/17/03  |  |

|   |  |  |                          |
|---|--|--|--------------------------|
| FORM PTO - 1449<br>INFORMATION DISCLOSURE STATEMENT |  | ATTORNEY DOCKET NO.: MERCK-2056<br>APPLICANTS: Hartmann <i>et al.</i><br>SERIAL NO.: 09/708,506      CONF. NO.: 2626<br>FILING DATE: November 9, 2000    GROUP: 1647   |                          |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |                          |
|   | C80  | Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.   |                          |
|   | C81  | Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , 348:555-557.  |                          |
|   | C82  | Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:6069-522-525.   |                          |
|   | C83  | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.  |                          |
|   | C84  | Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci.</u> , 83:4479-4483.  |                          |
|   | C85  | Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-micoglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci.</u> , 93:11:5512-5516.  |                          |
|   | C86  | Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci.</u> , 88:11120-11123.  |                          |
|   | C87  | Kappel et al., (1992), "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553   |                          |
|   | C88  | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc $\gamma$ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160:6:1686-1701.                                   |                          |
|   | C89  | Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunotherapy</u> , 48:219-229.   |                          |
|   | C90  | Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <u>Journal Immunology</u> , 158:9:4137-4144. |                          |
|   | C91  | Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.   |                          |
|   | C92  | Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 81:7922-7926.   |                          |
|   | C93  | Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152:6:1233-1246.  |                          |
|   | C94  | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268:31:23311-23317.   |                          |
| EXAMINER  |     |  | DATE CONSIDERED 12/19/03 |



|   |   |   |         |
|---|---|---|---------|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.: MERCK-2056</b><br><b>APPLICANTS: Hartmann et al.</b><br><b>SERIAL NO.: 09/708,506</b> <b>CONF. NO.: 2626</b><br><b>FILING DATE: November 9, 2000</b> <b>GROUP: 1647</b>                         |         |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |   |         |
| RM  | C95   | Lazar et al., (1988), "Transforming Growth Factor $\alpha$ Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8:3:1247-1252.              |         |
|   | C96   | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.   |         |
|   | C97   | Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nature Biotechnology</u> , 15:1:35-40.  |         |
|   | C98   | Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , 174:3:561-569.  |         |
|   | C99   | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 82:8648-8652.  |         |
|   | C100  | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.  |         |
|   | C101  | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92:10:3730-3736.         |         |
|   | C102  | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11:6:495-500.   |         |
|   | C103  | Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Thera.</u> , 80:3:277-292.  |         |
|   | C104  | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91:5:1706-1715.  |         |
|   | C105  | Lode et al., (1999), "Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci.</u> , 96:1591-1596.  |         |
|   | C106  | Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci.</u> , 96:8591-8596.                                     |         |
|   | C107  | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29:2:117-120.  |         |
|   | C108  | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84:8:2457-2466. |         |
|   | C109  | Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , 267:36:26166-26171.   |         |
| my  | C110  | Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146.                |         |
| <b>EXAMINER</b> RM  |   | <b>DATE CONSIDERED</b>  | 2/19/03 |



NOV 03 2003

SHEET 15 OF 19

|                                  |  |   |                 |
|----------------------------------|--|---|-----------------|
| FORM PTO - 1449                  |  | ATTORNEY DOCKET NO.: MERCK-2056   |                 |
| INFORMATION DISCLOSURE STATEMENT |  | APPLICANTS: Hartmann <i>et al.</i>  |                 |
|                                  |  | SERIAL NO.: 09/708,506  | CONF. NO.: 2626 |
|                                  |  | FILING DATE: November 9, 2000 GROUP: 1647   |                 |
| EXAM.<br>INIT.                   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |                 |
| <i>RD</i>                        | C111   | Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158:5:2211-2217.   |                 |
|                                  | C112   | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.  |                 |
|                                  | C113   | Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173.   |                 |
|                                  | C114   | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.  |                 |
|                                  | C115   | Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:4:473-492.  |                 |
|                                  | C116   | Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related $\alpha$ -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci.</u> , 83:8258-8262. |                 |
|                                  | C117   | Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , 123-140.  |                 |
|                                  | C118   | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13:17:6361-6373.  |                 |
|                                  | C119   | Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.  |                 |
|                                  | C120   | Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142.  |                 |
|                                  | C121   | Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.  |                 |
|                                  | C122   | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.   |                 |
|                                  | C123   | O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , 2:6:689-692.   |                 |
|                                  | C124   | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.  |                 |
|                                  | C125   | Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264:26:15157-15160.  |                 |
| <i>RD</i>                        | C126   | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.  |                 |
| EXAMINER <i>R. M. Weir</i>       |  | DATE CONSIDERED   | <i>2/19/03</i>  |



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056


APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506


CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647


| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |
|----------------|--|---|
|                | C127   | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , 163:166-178.                              |
|                | C128   | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal of Immunology</u> , 142:10:3662-3667.   |
|                | C129   | Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Research</u> , 59:1036-1040.   |
|                | C130   | Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , 94:20:10889-10894.                    |
|                | C131   | Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 27-53.   |
|                | C132   | Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , 7:2:S99-S106.   |
|                | C133   | Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , 343:1177-1183.  |
|                | C134   | Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor $\alpha$ and $\beta$ chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347. |
|                | C135   | Roitt et al., (1993), "The Role of Th Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8.3-8.4.  |
|                | C136   | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , 9:2:58-62.   |
|                | C137   | Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> , 2:3:159-173.   |
|                | C138   | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.   |
|                | C139   | Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , 17:15:4249-4256.                       |
|                | C140   | Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the $\alpha$ chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.  |
|                | C141   | Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci.</u> , 84:6904-6908.  |
|                | C142   | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , 148:11:3433-3340.   |
| EXAMINER       | DATE CONSIDERED 12/19/03   |   |



|   |   |   |  |
|---|---|---|--|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.: MERCK-2056</b><br><b>APPLICANTS: Hartmann et al.</b><br><b>SERIAL NO.: 09/708,506</b> <b>CONF. NO.: 2626</b><br><b>FILING DATE: November 9, 2000</b> <b>GROUP: 1647</b>   |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |   |  |
|   | C143  | Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:13:4842-4846.   |  |
|   | C144  | Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.   |  |
|   | C145  | Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>Journal of Immunology</u> , 163:5020-5028.  |  |
|   | C146  | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon- $\lambda$ and is not blocked by human IgG," <u>Journal of Immunology</u> , 137:11:3378-3382. |  |
|   | C147  | Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.   |  |
|   | C148  | Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci.</u> , 87:5322-5326.  |  |
|   | C149  | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.   |  |
|   | C150  | Stevenson et al., (1997), "Conjugation of Human Fc $\gamma$ in Closed-Hinge or Open-Hinge Configuration to Fab' $\gamma$ and Analogous Ligands," <u>Journal of Immunology</u> , 158:2242-2250.  |  |
|   | C151  | Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Research</u> , 60:247-267.   |  |
|   | C152  | Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , 302:305-309.   |  |
|   | C153  | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , 143:8:2595-2601.  |  |
|   | C154  | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , 178:2:661-667.   |  |
|   | C155  | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.  |  |
|   | C156  | <u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 <sup>th</sup> ed. 1999).  |  |
|   | C157  | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48:5:1119-1123  |  |
|   | C158  | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168  |  |
| <b>EXAMINER</b>   |   | <b>DATE CONSIDERED</b> 12/19/03   |  |



|   |   |  |  |
|---|---|--|--|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.: MERCK-2056</b><br><b>APPLICANTS: Hartmann et al.</b><br><b>SERIAL NO.: 09/708,506</b> <b>CONF. NO.: 2626</b><br><b>FILING DATE: November 9, 2000</b> <b>GROUP: 1647</b>  |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |  |  |
| <i>R.B.</i>   | C159  | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.                       |  |
|   | C160  | Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.   |  |
|   | C161  | Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , 44:681-687.  |  |
|   | C162  | Verhoeven et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.   |  |
|   | C163  | Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:1:12-20.                                |  |
|   | C164  | Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:9:3662-3672.  |  |
|   | C165  | Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , 43:319-324.  |  |
|   | C166  | Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <u>Protein Engineering</u> , 1:6:493-498. |  |
|   | C167  | Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>Journal Immunology</u> , 151: 6602-6607.                                  |  |
|   | C168  | Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.  |  |
|   | C169  | Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.  |  |
|   | C170  | Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," <u>Journal of Immunology</u> , 154:5590-5600.                                |  |
|   | C171  | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269:3469-3474.  |  |
|   | C172  | International Search Report for International Application No. PCT/EP00/10843, mailed July 20, 2001.  |  |
|   | C173  | Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," <u>J. Biol. Chem.</u> , 268:15983-15993.  |  |
|   | C174  | Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82:1507-1516.  |  |
| <i>Ry</i>   | C175  | Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227:1385-1388  |  |
| <b>EXAMINER</b> <i>R M Kelly</i>                                  |   | <b>DATE CONSIDERED</b> <i>12/19/00</i>   |  |



|   |   |  |  |
|---|---|--|--|
| <b>FORM PTO - 1449</b><br><b>INFORMATION DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.: MERCK-2056</b><br><b>APPLICANTS: Hartmann et al.</b><br><b>SERIAL NO.: 09/708,506</b> <b>CONF. NO.: 2626</b><br><b>FILING DATE: November 9, 2000</b> <b>GROUP: 1647</b>                              |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |  |  |
| <i>RM</i>   | C176  | Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13   |  |
|   | C177  | Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527  |  |
|   | C178  | Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131  |  |
|   | C179  | Maddougall, (2002), "Optimizing the Use of Erythropoietic Agents – Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70   |  |
|   | C180  | Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56   |  |
| <i>RY</i>   | C181  | Seidenfeld et al., (2001), "Epoetin Treatment of Anemia Associated with Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of the National Cancer Institute</u> , 93:1204-1214 |  |
| <b>EXAMINER</b> <i>R M Tooley</i>                                 |   | <b>DATE CONSIDERED</b> <i>12/19/03</i>   |  |

2679871-1